GlassScriptPhysician profile
Kelly E Greene
NPI 1790857340
$17,942.18
in general payments reported to CMS, 2019-2025
45 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $10K · 2021: $920 · 2022: $1,211 · 2023: $1,330 · 2024: $1,416 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,962.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $10,840.00 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,171.13 | 2019-2025 | Breztri, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $755.80 | 2021-2025 | Dupixent |
| Genzyme Corporation | $669.65 | 2019-2025 | |
| Grifols USA, LLC | $468.21 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.22 | 2019-2024 | Ofev |
| Merck Sharp & Dohme LLC | $227.97 | 2019-2025 | Winrevair, Zerbaxa, Recarbrio |
| Insmed, INC. | $227.08 | 2022-2025 | Arikayce, Brinsupri |
| Alexion Pharmaceuticals, INC. | $199.17 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $180.31 | 2020-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $168.16 | 2022-2025 | Glassia, Hyqvia |
| Lilly USA, LLC | $155.78 | 2025 | Zepbound, Mounjaro |
| Mylan Specialty L.P. | $137.96 | 2019-2022 | |
| Abbvie INC. | $137.87 | 2023-2025 | |
| Boston Scientific Corporation | $123.52 | 2023 | Watchman |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.